Versant Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Versant Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41.5K	Buy	3,032 +2,627	+649%	+$27.5K	﹤0.01%	1529
2026 Q2	$2.72K	Buy	405 +90	+29%	+$709	﹤0.01%	2527
2026 Q1	$2.43K	Buy	315 +50	+19%	+$365	﹤0.01%	2533
2025 Q4	$1.62K	Buy	265 +204	+334%	+$2.2K	﹤0.01%	2468
2025 Q3	$1.12K	Hold	61	–	–	﹤0.01%	2492
2025 Q2	$794	Sell	61 -137	-69%	-$1.62K	﹤0.01%	2512
2025 Q1	$2.1K	Buy	198 +142	+254%	+$2.25K	﹤0.01%	2264
2024 Q4	$950	Hold	56	–	–	﹤0.01%	2207
2024 Q3	$1.3K	Buy	+56	New	+$1.2K	﹤0.01%	1680

Other funds holding ARCT

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Versant Capital Management's ARCT Position: Q3 2026 in Review

Versant Capital Management increased its Arcturus Therapeutics (ARCT) stake by 649% in Q3 2026, buying an estimated $27.5K and bringing the position to 3,032 shares worth $41.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1529.

Versant Capital Management first reported a position in ARCT in Q3 2024 and has held it in 9 quarters since. 70 funds tracked by Wall St. Rank hold ARCT as of Q3 2026.

Versant Capital Management held 3,032 shares of Arcturus Therapeutics worth $41.5K as of Q3 2026.
Versant Capital Management bought 2,627 Arcturus Therapeutics shares in Q3 2026, an estimated $27.5K.
Arcturus Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1529 holding.
Versant Capital Management first reported a position in Arcturus Therapeutics in Q3 2024 and has held it in 9 quarters since.
70 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.